Edge Therapeutics
acquired by PDS Biotechnology Corp.Berkeley Heights, US · Delaware corporation · 1 known investors
Find your way into Edge Therapeutics
352 people in our graph share verified history with the Edge Therapeutics team — schools, employers, funds. One of them is your warm intro.
Jung Lee, PhDunlockedknows Brian A. Leuthner · together at GSK (overlapped)
×9knows the team · via UNC Kenan-Flagler Business School
×2knows the team · via Cardinal Health
Acquired by PDS Biotechnology Corporation March 2019 · terms undisclosed · source ↗
Hospital-based therapies for acute, life-threatening neurological conditions. (NASDAQ: EDGE)
Founders & leadership
RL
Robert Loch MacdonaldCo-founder
BA
Brian A. LeuthnerinCo-founderBrian A. Leuthner is Executive Officer and Director at Edge Therapeutics, a public biotech company developing hospital-based therapies for acute neurological conditions. He brings over 30 years of experience in drug development and commercialization, including prior roles leading private and public companies through IPO.
AE
Andrew EinhornExecutive
AN
Albert N. Marchio IIExecutive
HJ
Herbert J. FaleckExecutive
CJ
Carl J. SorannoNamed on SEC filing
Board
IB
Isaac BlechBoard director
JL
James LoughlinBoard director
RS
Robert SpiegelBoard director
KC
Kurt ContiBoard director
SJ
Sol J. BarerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$63.9M disclosed across 2 rounds · 2014–2015
▶$56MraisedApr 2015 · 19 investors · PharmaceuticalsRule 506(b)
▶$56MraisedApr 2015 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew EinhornExecutive Officer
- James LoughlinDirector
- Isaac BlechDirector
- Albert N. Marchio IIExecutive Officer
- Robert SpiegelDirector
- Kurt ContiDirector
- Robert Loch MacdonaldExecutive Officer, Director
- Herbert J. FaleckExecutive Officer
- Sol J. BarerDirector
- Carl J. SorannoExecutive Officer
- Brian A. LeuthnerExecutive Officer, Director
- Offering amount
- $56M
- Amount sold
- $56M
- Finders' fees
- $3.3M
- Placement agents
- Credit Suisse Securities (USA) LLC, Leerink Partners LLC, Maxim Group, LLC
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.9MraisedNov 2014 · 104 investors · PharmaceuticalsRule 506(b)
▶$7.9MraisedNov 2014 · 104 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Albert N. Marchio IIExecutive Officer
- Robert Loch MacdonaldExecutive Officer, Director
- Robert SpiegelDirector
- Carl J. SorannoExecutive Officer
- Brian A. LeuthnerExecutive Officer, Director
- James LoughlinDirector
- Herbert J. FaleckExecutive Officer
- Sol J. BarerDirector
- Andrew EinhornExecutive Officer
- Isaac BlechDirector
- Kurt ContiDirector
- Offering amount
- $25M
- Amount sold
- $7.9M
- Minimum investment
- $10K
- Sales commissions
- $595.9K
- Placement agents
- Maxim Group LLC
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Edge Therapeutics do?
- Hospital-based therapies for acute, life-threatening neurological conditions. (NASDAQ: EDGE)
- Who founded Edge Therapeutics?
- Edge Therapeutics was founded by Robert Loch Macdonald, Brian A. Leuthner.
- Who are Edge Therapeutics's investors?
- Edge Therapeutics's investors include Sofinnova Ventures.
- How much funding has Edge Therapeutics raised?
- Edge Therapeutics has disclosed $63.9M raised across 2 rounds.
- Who acquired Edge Therapeutics?
- Edge Therapeutics was acquired by PDS Biotechnology Corp..
- Where is Edge Therapeutics headquartered?
- Edge Therapeutics is headquartered in Berkeley Heights, US.